Table 1.
Participant demographic and clinical characteristics (mean, SD; %, n; median, interquartile range)
| HIV-(n = 150) | HIV+ no HAND (n = 131) | HAND (n = 72) | p-value | |
|---|---|---|---|---|
| Age (years) | 43.4 (15.5) | 45.2 (13.2) | 46.3 (13.9) | .32 |
| Education (years) | 13.9 (2.3) | 13.7 (2.3) | 13.3 (2.6) | .23 |
| Gender (% M) | 70.0% | 84.0% | 87.5% | .002 |
| Ethnicity (% Caucasian) | 55.3% | 59.5% | 50.0% | .81 |
| LT affective disordera (%) | 37.3% | 69.5% | 56.1% | <.001 |
| LT substance use disorder (%) | 60.0% | 78.6% | 65.3% | .003 |
| AIDS (%) | – | 50.1% | 56.9% | .40 |
| Nadir CD4 | – | 204 (100, 332) | 162 (50, 328.8) | .11 |
| Current CD4 | – | 558 (384, 797.5) | 517 (376.8, 732) | .36 |
| Plasma VL Detectable | – | 19.7% (25) | 24.6% (17) | .42 |
| CSF VL detectable | – | 21.4% (21) | 12.7% (7) | .18 |
| % On antiretrovirals | – | 87.0% | 87.5% | .92 |
| Duration of infection (years) | – | 13.1 (4.0, 20.4) | 13.2 (3.8, 20.6) | .84 |
Notes: HAND, HIV-associated neurocognitive disorder; LT, lifetime; CSF, cerebral spinal fluid; VL, viral load.
aMet DSM-IV-TR criteria for lifetime major depressive disorder or generalized anxiety disorder.